Advances in the treatment of Hodgkin's lymphoma (Review)

被引：3

作者：

Che, Yuxuan ^{[1
]}

Ding, Xiaolei ^{[1
]}

Xu, Liye ^{[1
]}

Zhao, Jian ^{[1
]}

Zhang, Xian ^{[1
]}

Li, Na ^{[1
]}

Sun, Xiuhua ^{[1
,2
]}

机构：

[1] Dalian Med Univ, Dept Oncol, Hosp 2, Dalian 116021, Liaoning, Peoples R China

[2] Dalian Med Univ, Dept Oncol, Hosp 2, 467 Zhongshan Rd, Dalian 116021, Liaoning, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2023年 / 62卷 / 05期

关键词：

novel therapies; Hodgkin's lymphoma; brentuximab vedotin; immunotherapy; targeted therapy; cell therapy; STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; OPEN-LABEL; SINGLE-ARM; T-CELLS; FOLLOW-UP; ANTITUMOR-ACTIVITY; CHECKMATE; 205; STAGE-III;

D O I：

10.3892/ijo.2023.5509

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hodgkin's lymphoma (HL) is a unique B-cell lymphoproliferative malignancy that has a critical pathogenesis characterized by a sparse population of Hodgkin and Reed-Sternberg cells surrounded by numerous dysfunctional immune cells. Although systemic chemotherapy with or without radiotherapy, has significantly improved the prognosis of the majority of patients with HL, a subset of patients remains refractory to first-line therapy or relapse after achieving an initial response. With the increased understanding of the biology and microenvironment of HL, novel strategies with notable efficacy and manageable toxicity, including targeted therapies, immunotherapy and cell therapy have emerged. The present review summarizes the progress made in developing novel therapies for HL and discusses future research directions in HL therapy.

引用

页数：14

共 116 条

[1]

Ansell S, 2021, CL LYMPH MYELOM LEUK, V21, pS373

[2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[3] PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation [J].

Armand, Philippe ;

Chen, Yi-Bin ;

Redd, Robert A. ;

Joyce, Robin M. ;

Bsat, Jad ;

Jeter, Erin ;

Merryman, Reid W. ;

Coleman, Kimberly C. ;

Dahi, Parastoo B. ;

Nieto, Yago ;

LaCasce, Ann S. ;

Fisher, David C. ;

Ng, Samuel Y. ;

Odejide, Oreofe O. ;

Freedman, Arnold S. ;

Kim, Austin, I ;

Crombie, Jennifer L. ;

Jacobson, Caron A. ;

Jacobsen, Eric D. ;

Wong, Jeffrey L. ;

Patel, Sanjay S. ;

Ritz, Jerome ;

Rodig, Scott J. ;

Shipp, Margaret A. ;

Herrera, Alex F. .

BLOOD, 2019, 134 (01) :22-29

[4] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[5] Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents [J].

Bartlett, JB ;

Dredge, K ;

Dalgleish, AG .

NATURE REVIEWS CANCER, 2004, 4 (04) :314-322

[6]

Bartlett NL, 2018, Blood, V132, P1620, DOI [DOI 10.1182/BLOOD-2018-99-118506, 10.1182/ /blood -2018-99-118506]

[7] Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].

Beatty, Gregory L. ;

Haas, Andrew R. ;

Maus, Marcela V. ;

Torigian, Drew A. ;

Soulen, Michael C. ;

Plesa, Gabriela ;

Chew, Anne ;

Zhao, Yangbing ;

Levine, Bruce L. ;

Albelda, Steven M. ;

Kalos, Michael ;

June, Carl H. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120

[8] Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial [J].

Boell, Boris ;

Pluetschow, Annette ;

Buerkle, Carolin ;

Atta, Johannes ;

Pfreundschuh, Michael ;

Feuring-Buske, Michaela ;

Vogelhuber, Martin ;

Soekler, Martin ;

Eichenauer, Dennis A. ;

Thielen, Indra ;

von Tresckow, Bastian ;

Fuchs, Michael ;

Engert, Andreas ;

Borchmann, Peter .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (01) :42-52

[9] A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC [J].

Boles, Kent S. ;

Vermi, William ;

Facchetti, Fabio ;

Fuchs, Anja ;

Wilson, Timothy J. ;

Diacovo, Thomas G. ;

Cella, Marina ;

Colonna, Marco .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (03) :695-703

[10] Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma [J].

Borchmann, P ;

Schnell, R ;

Fuss, I ;

Manzke, O ;

Davis, T ;

Lewis, LD ;

Behnke, D ;

Wickenhauser, C ;

Schiller, P ;

Diehl, V ;

Engert, A .

BLOOD, 2002, 100 (09) :3101-3107

← 1 2 3 4 5 6 7 8 9 10 →